DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 minute ago

CI·The Cigna Group

$.
-. (-.%)
After Hours
High
$288.00
Open
$283.00
Market Cap
74.18B
52W High
$338.89
Low
$279.67
P. Close
$280.97
P/E
11.80
52W Low
$239.51
Fwd P/E
8.39
Mean Target
$341.75
Technical Score (1D)
64
BUY
News Sentiment
39
BEARISH
Barclays has downgraded Cigna Group (CI) shares, causing a notable decline in its stock price. This analyst action signals a shift in sentiment that could influence investor perception of the company's near-term outlook. Investors will be monitoring for additional commentary or company disclosures to clarify the reasons behind this downgrade.
Earnings Summary
The Cigna Group is a U.S.-based healthcare company operating within the Healthcare sector, specifically in the Healthcare Plans industry. It delivers comprehensive health solutions through its Evernorth Health Services and Cigna Healthcare segments, offering pharmacy benefits management, care delivery, and insurance products. In its most recent reported quarters, Cigna demonstrated a pattern of exceeding analyst expectations for Earnings Per Share (EPS). For Q2 2026, the company reported an actual EPS of $7.20 against an estimate of $7.15, and in Q3 2025, actual EPS was $7.83 versus an estimate of $7.64. This follows a trend where the company beat EPS estimates in three of the last four reported quarters, indicating a consistent ability to outperform projections. Revenue figures, where available, show a general upward trend, with Q4 2025 revenue at $72.495 billion and Q1 2026 revenue at $68.517 billion, though revenue estimates were not consistently provided for all periods. Recent news highlights a divergence in analyst sentiment, with Deutsche Bank initiating a 'sell' rating while Morgan Stanley maintained an 'Overweight' rating and raised its price target. Cigna also raised its full-year 2026 adjusted EPS guidance, signaling positive momentum. Investors will be watching for how Cigna navigates potential disruptions in the pharmacy benefit manager sector due to AI and for continued performance against analyst estimates in upcoming quarters, particularly concerning the recurrence of unusual expenses that impacted statutory profit.

EPS

EstBeatMiss
$6.09$6.65$7.21$7.78$8.34Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$7.56 - -
Q1'26$7.61$7.79+2.4%
Q4'25$7.50$8.08+7.8%
Q3'25$7.64$7.83+2.5%
Q2'25$7.15$7.20+0.6%
Q1'25$6.35$6.74+6.2%

Revenue

EstBeatMiss
$64.5B$66.7B$69.0B$71.3B$73.5BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$72.4B - -
Q1'26$66.2B$68.5B+3.5%
Q4'25$66.4B$72.5B+9.2%
Q3'25 - $69.7B -
Q2'25 - $67.2B -
Q1'25 - $65.5B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

CI Stock Snapshot

CI is currently trading at $281.40, giving The Cigna Group a market cap of 74.18B and a P/E ratio of 11.8. Today's range spans $279.67–$288.00, with shares opening at $283.00 and moving up $0.43 (0.2%) from the prior close. DailyIQ's technical score sits at 64/100 (HOLD) with a news sentiment reading of 39/100.

Over the past year CI has traded between $239.51 and $338.89 - the current price is +17.5% off the 52-week low and -17.0% from the high. 36 analysts cover the stock with a Buy consensus and a mean 12-month target of $341.75 (range $290.00–$400.00), implying upside of +21.4%.

The Cigna Group (CI) is a large-cap in Healthcare with 74.18B in market cap, currently sitting on a HOLD signal at 64/100. Price: $281.40 (in the middle of its 52-week range). Sentiment: bearish at 39/100. The current P/E ratio stands at 11.8. The 52-week range of $239.51–$338.89 is the structural anchor, and the current neutral phase is the market's way of asking for more information before committing to a direction.

Portfolio construction in Healthcare often uses large-cap names like CI as tactical swing positions during neutral phases: cheap enough to overweight, liquid enough to exit quickly, and large enough to provide meaningful sector beta. The current 64/100 (HOLD) at $281.40 (in the middle of its 52-week range) and bearish sentiment (39/100) frame the position as a catalyst play within the $239.51–$338.89 annual range rather than a directional bet.